Benefit From OTC Switches Supported In Study Of PPIs' Outpatient Impact
This article was originally published in The Pink Sheet
Proton pump inhibitor OTC switches since 2003 had a profound and sustained impact on outpatient health care visits – illustrating the potential for other switches to benefit US health care, a recent study suggests.
You may also be interested in...
Perrigo's omeprazole and sodium bicarbonate capsules indicated for the treatment of frequent heartburn will bear labeling that has been through several updates since the first PPI became available OTC in 2004.
Merck’s silence on an OTC version of Singulair is a sign of the relatively “quiet” 2015 switch market despite the call for novel switches, particularly to treat chronic conditions, from FDA’s Nonprescription Drug Safe Use Regulatory Expansion Initiative.
OTC switch product sales are estimated to grow at a compounded annual growth rate of 5% by 2019, with opportunities likely emerging in bladder control for women and sleep aids, according to Kline Market Research. But asthma drugs and statins are not likely to debut OTC soon, notes analyst Laura Mahecha.